AZN - China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients | Benzinga
On Wednesday, China approved AstraZeneca plc's (NYSE:AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy for the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer whose tumors have exon 19 deletions or exon 21 mutations.
On Tuesday, the Tagrisso with pemetrexed and platinum-based chemotherapy regime received approval in Japan for the same indication.
China's National Medical Products Administration approved the drug based on the results of the FLAURA2 Phase 3 trial, which were published in the New England Journal of Medicine.
In the overall trial population, Tagrisso, with ...